發(fā)布時(shí)間：2018-05-18 09:02

  本文選題：乳腺癌 + 超聲�。� 參考：《甘肅醫(yī)藥》2016年10期

【摘要】：目的:采用Meta分析方法評價(jià)超聲、鉬靶以及聯(lián)合應(yīng)用在乳腺癌診斷中的臨床價(jià)值。方法:計(jì)算機(jī)檢索Pub Med、Web of Science、The Cochrane Library、萬方數(shù)據(jù)庫、中國知網(wǎng)、中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫,并輔以手工檢索,獲取超聲和鉬靶在乳腺癌診斷的相關(guān)文獻(xiàn)。依據(jù)診斷準(zhǔn)確性研究的質(zhì)量評估(QUADAS-2)工具進(jìn)行文獻(xiàn)質(zhì)量評價(jià)。利用Meta-Disc1.4和Rev Man 5.2軟件對超聲和鉬靶診斷乳腺癌的敏感性(SEN)、特異性(SPE)、陽性似然比(+LR)、陰性似然比(-LR)、診斷比值比(DOR)進(jìn)行合并分析,并計(jì)算綜合受試者工作特征(SROC)曲線下面積。結(jié)果:Meta分析結(jié)果顯示,以術(shù)后病理檢查為金標(biāo)準(zhǔn),乳腺超聲診斷乳腺癌的SEN合并為0.85(95%CI:0.84,0.86),SPE合并為0.93(95%CI:0.92,0.93),DOR為20.35(95%CI:13.62,30.4);鉬靶X線診斷乳腺癌的SEN合并為0.81(95%CI:0.80,0.83),SPE合并為0.97(95%CI:0.97,0.97),DOR為19.49(95%CI:11.29,33.66);乳腺超聲聯(lián)合鉬靶X線診斷乳腺癌的SEN合并為0.94(95%CI:0.93,0.95),SPE合并為0.93(95%CI:0.92,0.94),DOR為89.24(95%CI:46.14,172.63)。結(jié)論:乳腺超聲和鉬靶X線診斷乳腺癌的準(zhǔn)確性較高,兩者效果相當(dāng),聯(lián)合應(yīng)用更能有效地提高診斷乳腺癌的準(zhǔn)確性。
[Abstract]:Objective: to evaluate the clinical value of ultrasound, molybdenum target and combined application in the diagnosis of breast cancer by Meta. Methods: the Pub Medence web of the Cochrane Library, Wanfang Database, China knowledge Network, Chinese Biomedical Literature Database were searched by computer, and the relevant documents of ultrasound and molybdenum target in breast cancer diagnosis were obtained by hand search. The literature quality was evaluated according to the QUADAS-2 tool of diagnostic accuracy study. The sensitivity, specificity, positive likelihood ratio (LRN), negative likelihood ratio (NLR) and diagnostic ratio (OR) of ultrasound and molybdenum target in the diagnosis of breast cancer were analyzed by Meta-Disc1.4 and Rev Man 5.2, and the area under the curve was calculated. Results the results of the meta-analysis showed that the postoperative pathological examination was regarded as the gold standard. 涔寵吅瓚呭０璇婃柇涔寵吅鐧岀殑SEN鍚堝茍涓，

本文編號：1905242